EQS-News: Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy
EQS-News: Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy
EQS-News: Marinomed Biotech AG / Key word(s): Alliance
Marinomed Biotech AG Announces Strategic Partnership and Worldwide
Licensing for Marinosolv® Technology in Inhalation Therapy
19.05.2026 / 07:58 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG Announces Strategic Partnership and Worldwide
Licensing for Marinosolv® Technology in Inhalation Therapy
• Marinomed signs term sheet with Phargentis SA for a worldwide
exclusive license of the Marinosolv® technology platform for an
inhalation formulation.
• Partnership includes fee-for-service development, long-term milestone
payments, and future royalties on product sales.
• The collaboration leverages Marinomed’s expertise to enhance
solubility and bioavailability of a specialized respiratory
therapeutic.
Korneuburg, Austria, May 19^th, 2026 – Marinomed Biotech AG (VSE:MARI), a
dynamic biopharmaceutical company, today announced the signing of a term
sheet with Phargentis SA. The term sheet contains the worldwide licensing
of the proprietary Marinosolv® technology platform for the development of
a high-performance formulation with a combination of different active
pharmaceutical ingredients specifically designated for inhalation.
Under the terms of the agreement, Marinomed will provide specialized
formulation services and technical expertise to develop a respiratory
therapeutic utilizing the Marinosolv® platform. This technology is
designed to significantly increase the solubility and bioavailability of
hydrophobic compounds, enabling more effective delivery to the lungs and
potentially reducing the required dosage for patients.
The financial structure of the partnership includes immediate
fee-for-service components for the initial development phases.
Furthermore, Marinomed is eligible to receive milestone payments tied to
specific technical and clinical achievements throughout the development
lifecycle, spanning several years. Upon successful commercialization, the
agreement also stipulates the payment of royalties on net sales of the
resulting product.
„This agreement marks another significant milestone in our strategy to
monetize the Marinosolv® platform beyond our own internal pipeline,“ said
Andreas Grassauer, CEO of Marinomed. „By applying our technology to
inhalation therapies, we are addressing a critical need for better
delivery of poorly soluble drugs in respiratory medicine. This partnership
not only validates the versatility of our patent portfolio but also
provides a sustainable revenue stream through services, milestones, and
future royalties.“
The Marinosolv® technology has already demonstrated its capability in
various ophthalmic and nasal applications. This latest expansion into
inhalation underscores the platform’s potential to revolutionize treatment
paradigms across multiple therapeutic areas where drug solubility remains
a barrier to clinical success.
About Marinosolv®
Marinosolv® is Marinomed’s proprietary technology platform designed to
increase the solubility of hardly soluble compounds. This enables the
development of aqueous formulations for sensitive tissues such as the
eyes, nose, and lungs without the need for harsh solvents or
preservatives, thereby improving both efficacy and local tolerability.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: [1] https://www.marinomed.com.
About Phargentis SA
Phargentis, founded in 2015 and headquartered in Lugano Switzerland,
develops Generic and innovative Super Generic products for the respiratory
market with a strong focus on COPD and Asthma. Phargentis is an agile
company that leverages robust global partnerships to execute a unique
Early Market Entry strategy for Generics and global out-licensing for its
diverse, competitive portfolio. Phargentis is co-owned by Chemholding
(Switzerland), Helm Swiss (Switzerland) and Pharmaxis (Dubai). Its
flagship product is generic Tiotropium bromide DPI, the fully
interchangeable generic version of the world’s first-line COPD treatment,
achieved European sales and is being planned to launch in other key
markets.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com
E-Mail: [3]ir@marinomed.com
Disclaimer
The new shares and subscription rights have not been and will not be
registered under foreign securities laws – in particular under the U.S.
Securities Act of 1933, as amended („Securities Act“) – with foreign
securities authorities and may not be offered or sold, in particular in
the United States of America („US“), without registration or an exemption
from the registration requirements under the Securities Act. This
communication is not intended for distribution to or within the US and may
not be distributed or forwarded to publications with general circulation
in the US. This communication constitutes neither an offer to sell nor an
invitation to subscribe for or purchase securities in any jurisdiction in
which such an offer or such an invitation would be unlawful.
══════════════════════════════════════════════════════════════════════════
19.05.2026 CET/CEST This Corporate News was distributed by [4]EQS Group
View original content: [5]EQS News
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2329490
End of News EQS News Service
2329490 19.05.2026 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls2.ssx?fn=show_t_gif&application_id=2329490&application_name=news&site_id=apa_ots_austria~~
References
~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2329490&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=150d4456ab8cdf771506c5ac542ad01a&application_id=2329490&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender